Mauna Kea Technologies: First Half 2026 Review

Mauna Kea Technologies announced a 37% increase in product and service revenue, reaching €3.2 million in the first half of 2026. This growth was primarily driven by the strong performance of CellTolerance in Europe and expansion into new markets. Gross margin improved to 65% despite operating expenses of €5.9 million. R&D spending and general overheads both declined slightly.

The company has strengthened its financial visibility through the end of 2027 thanks to the continued support of Vester Finance. Clinical advances, particularly in the evaluation of pancreatic cysts and Barrett's esophagus, reinforce the position of Cellvizio, their flagship device, in interventional endoscopy. In the United States, the business model has evolved with Clinical Associates to support the use of Cellvizio.